Show simple item record

dc.contributor.authorClarke, Noel W
dc.contributor.authorThiery-Vuillemin, A
dc.contributor.authorWiechno, PJ
dc.contributor.authorAlekseev, B
dc.contributor.authorSala, N
dc.contributor.authorJones, R
dc.contributor.authorKocak, I
dc.contributor.authorChiuri, VE
dc.contributor.authorJassem, J
dc.contributor.authorFlechon, A
dc.contributor.authorRedfern, C
dc.contributor.authorGoessl, CD
dc.contributor.authorBurgents, J
dc.contributor.authorGresty, C
dc.contributor.authorDegboe, A
dc.contributor.authorSaad, F
dc.date.accessioned2019-11-19T16:01:09Z
dc.date.available2019-11-19T16:01:09Z
dc.date.issued2019en
dc.identifier.citationClarke NW, Thiery-Vuillemin A, Wiechno PJ, Alekseev B, Sala N, Jones R, et al. Health-related quality of life (HRQoL) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in combination with abiraterone. J Clin Oncol. 2019;37(7_suppl):234-.en
dc.identifier.doi10.1200/JCO.2019.37.7_suppl.234en
dc.identifier.urihttp://hdl.handle.net/10541/622473
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2019.37.7_suppl.234en
dc.titleHealth-related quality of life (HRQoL) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in combination with abirateroneen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThe Christie and Salford Royal Hospitals, Manchesteren
dc.identifier.journalJournal of Clinical Oncologyen


This item appears in the following Collection(s)

Show simple item record